-$0.17 EPS Expected for Rexahn Pharmaceuticals, Inc. (RNN) This Quarter

Share on StockTwits

Equities analysts expect that Rexahn Pharmaceuticals, Inc. (NASDAQ:RNN) will announce ($0.17) earnings per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Rexahn Pharmaceuticals’ earnings. The highest EPS estimate is ($0.15) and the lowest is ($0.20). Rexahn Pharmaceuticals reported earnings of ($0.15) per share in the same quarter last year, which suggests a negative year over year growth rate of 13.3%. The firm is scheduled to issue its next earnings results on Monday, November 5th.

According to Zacks, analysts expect that Rexahn Pharmaceuticals will report full year earnings of ($0.59) per share for the current fiscal year, with EPS estimates ranging from ($0.65) to ($0.49). For the next fiscal year, analysts expect that the company will post earnings of ($0.58) per share, with EPS estimates ranging from ($0.62) to ($0.53). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Rexahn Pharmaceuticals.

Rexahn Pharmaceuticals (NASDAQ:RNN) last announced its earnings results on Monday, August 6th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.03.

Several brokerages have commented on RNN. Ifs Securities upgraded shares of Rexahn Pharmaceuticals from an “outperform” rating to a “strong-buy” rating in a report on Thursday, October 4th. B. Riley restated a “buy” rating on shares of Rexahn Pharmaceuticals in a report on Tuesday, July 31st.

RNN stock traded up $0.04 during mid-day trading on Friday, hitting $1.19. 600 shares of the company were exchanged, compared to its average volume of 272,638. Rexahn Pharmaceuticals has a 1-year low of $1.03 and a 1-year high of $2.70.

Rexahn Pharmaceuticals Company Profile

Rexahn Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The company's clinical stage drug candidates include RX-3117, which is in Phase II a clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase II a clinical study to treat patients with metastatic triple negative breast cancer.

See Also: Bear Market – How and Why They Occur

Get a free copy of the Zacks research report on Rexahn Pharmaceuticals (RNN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply